Dambkowski Carl sold $3.5M of APGE
Dambkowski Carl (Chief Medical Officer) sold 26,400 shares of Apogee Therapeutics, Inc. (APGE) at $132.60 ($3.50M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s post-transaction holdings but does not introduce new company performance or forward-looking guidance.
Market read
Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a major repricing absent other catalysts.
What to watch
Check whether there are concurrent insider buys/sales, changes in other executives’ activity, or any nearby company-specific catalysts (trial readouts, guidance, financing).
Background
This is an SEC Form 4 insider transaction disclosure for Apogee Therapeutics, Inc.
Ticker impact
Apogee Therapeutics CMO Dambkowski Carl sold 26,400 shares at $132.60 via an open-market sale under a 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely short-lived unless paired with other news.
The filing is a scheduled 10b5-1 sale by an officer; the article provides no new operational, clinical, or guidance information.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated.
None indicated.
Counterpoint
A 10b5-1 plan sale can be purely mechanical (tax/portfolio rebalancing) and may not reflect bearish fundamentals.
Key entities
- issuerApogee Therapeutics, Inc.
Company whose officer insider sale is disclosed on Form 4.
- insiderDambkowski Carl
Chief Medical Officer who executed an open-market sale under a pre-arranged 10b5-1 plan.
